Marinomed Biotech AG Partners to Launch Budesolv in Switzerland

Marinomed Biotech AG has entered into a partnership with a Swiss pharmaceutical company for the development and marketing of Budesolv in Switzerland. This binding term sheet grants the partner exclusive rights to sell and distribute Budesolv under its own brand in Switzerland. The agreement involves completing the necessary steps for obtaining marketing authorization.

In exchange, Marinomed will receive upfront and milestone payments, alongside royalties on sales. Additionally, Switzerland will act as a reference market for further international opportunities. The CEO of Marinomed, Andreas Grassauer, expressed optimism about the potential for future partnerships, driven by successful registration in Switzerland.